PNV - Banter and General Comments, page-11311

In an article
Coloplast’s acquisition of Kerecis: Considerations and implications

PNV has been listed among short list of players that have successfully achieved commercial penetration at scale


1. Only a handful of players have successfully achieved commercial penetration at scale

There are around 100 advanced wound care CTPs available in the US, which makes up roughly half of the global AWC market overall, and the overwhelming majority of AWC CTPs. However, relatively few players have managed to successfully take this AWC category from concept to successful commercialization in the years since wound care has been on the map with specialized care settings and reimbursement.
Indeed, various platforms based on everything from dehydrated porcine, bovine, ovine, and equine (pig, cattle, sheep, and horse) tissues, to autologous cells, cell culture banks, and human cadaver skin, to various amniotic and placental tissues, to collagen derived from bio-engineered plants, to bioactive glass and other synthetic materials have all been shown to contribute to healing in complex wounds and burns.
However, of these ~100 products / platforms, only a handful of companies have achieved significant commercial traction to date (some of these companies have multiple AWC CTP products in their portfolios):

• Organogenesis
• Smith+Nephew (portfolios acquired from Healthpoint and Osiris Therapeutics)
• MiMedx
• Integra Life Sciences
• Kerecis
• A few others could be added, depending on the thresholds considered, such as:
  • Convatec (via its acquisition of Triad Life Sciences in 2022)
  • Medline
  • Life Net Health (acquired the combined Bioventus-Misonix-Sol Systems wound portfolio earlier this year)
  • MTF Biologics
  • PolyNovo

So out of ~100 technologies, only about ~5-10 have significant commercial traction. Of these, Kerecis and its fish-derived Omega3 platform has been the fastest growing company in this segment for multiple years.